Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 800 of 1,261

  1. US 8796444

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  2. US 8796436

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  3. US 8796453

    Processes and intermediates for producing azaindoles

    Vertex Pharmaceuticals Incorporated · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  4. US 8796435

    Modular functional peptides for the intracellular delivery of nanoparticles

    United States of America as represented by the Secretary of the Air Force · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  5. US 8796322

    Methods for using 1,2,4-oxadiazole benzoic acid compounds

    PTC THERAPEUTICS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  6. US 8796327

    Method for inhibiting production of cytokines of T helper cell type II and/or inhibiting production of chemokines using brazilin

    China Medical University · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  7. US 8796320

    1,3,4-Oxadiazole-2-carboxamide compound

    Pharmadesign, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  8. US 8796270

    N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

    GILEAD CONNECTICUT, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  9. US 8796302

    Methods related to the treatment of neurodegenerative and inflammatory conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  10. US 8796291

    A3 adenosine receptor antagonists and partial agonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  11. US 8796254

    Methods for using carboxamide, sulfonamide and amine compounds

    Rigel Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  12. US 8796233

    Methods and systems for modulating hormones and related methods, agents and compositions

    The Regents of the University of California · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  13. US 8795738

    Use of arsenic for cancer therapy protection

    The Board of Regents of the University of Texas System · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  14. US 8796428

    Erk1/2 posphorylation site specific antibody

    Julius-Maximilians-Universitat Wurzburg · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  15. US 8796438

    Nucleic acids encoding inactive variants of human telomerase

    The Regents of the University of Colorado · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  16. US 8796308

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  17. US 8795669

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  18. US 8796332

    Compositions and methods for controlling infections

    Regents of the University of Minnesota · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  19. US 8791136

    Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  20. US 8790869

    Renal cell carcinoma biomarkers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  21. US 8790878

    Diagnosis and treatment of breast cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  22. US 8791244

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  23. US 8790695

    Medicinal carriers, and preparation method and uses thereof

    China Medical University · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  24. US 8790679

    Intracutaneous paste composition

    XERIS PHARMACEUTICALS, INC. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.